

Application No.: 09/446783  
Filing Date: May 16, 2000  
Response to Office Action mailed 02/10/2004  
Page 2 of 11

Attorney Docket No.: VPHAR1460-2  
(ABI1460-2 (071243-1301))

Amendments to the Claims/Listing of Claims

Please amend claim 73, and cancel claims 101, 102 and 107 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1-72. (Cancelled).

73. (Currently amended) An article of manufacture comprising a dry powder or liquid formulation of water insoluble drug and at least one protein,

wherein said formulation comprises a solid core of amorphous, water insoluble drug nanoparticles coated with said protein, and

wherein said drug nanoparticles are in amorphous form protein is albumin.

74. (Previously presented) An article of manufacture according to claim 73 wherein said drug is a taxane.

75. (Previously presented) An article of manufacture according to claim 74, wherein said liquid formulation of taxane is free of surfactants.

76-102. (Cancelled)

103. (Previously presented) An article of manufacture according to claim 73 wherein said drug is selected from the group consisting of an anti-neoplastic, an immunosuppressive, and an anesthetic.

104. (Previously presented) An article of manufacture according to claim 103 wherein said anti-neoplastic is a taxane.

105. (Previously presented) An article of manufacture according to claim 103 wherein said anesthetic is propofol.

Application No.: 09/446783  
Filing Date: May 16, 2000  
Response to Office Action mailed 02/10/2004  
Page 3 of 11

Attorney Docket No.: VPHAR1460-2  
(ABI1460-2 (071243-1301))

106-107. (Canceled).

108. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by oral, topical, ocular, intramuscular, intravenous, intraperitoneal, intraarterial, intraurethral, intrathecal, or inhalation administration.

109-121. (Cancelled)

122. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by oral administration.

123. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by topical administration.

124. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by ocular administration.

125. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intramuscular administration.

126. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intravenous administration.

127. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intraperitoneal administration.

Application No.: 09/446783  
Filing Date: May 16, 2000  
Response to Office Action mailed 02/10/2004  
Page 4 of 11

Attorney Docket No.: VPHAR1460-2  
(ABI1460-2 (071243-1301))

128. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intraarterial administration.

129. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intraurethral administration.

130. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intrathecal administration.

131. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by inhalation administration.

132. (Previously presented) An article of manufacture according to claim 73 wherein the average diameter of said nanoparticles is in the range of about 0.01 – 1 microns.

133. (Previously presented) An article of manufacture according to claim 103 wherein said immunosuppressive is cyclosporin.